Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited.

Denis, Marc G; Herbreteau, Guillaume; Pons-Tostivint, Elvire

Denis, Marc G; Herbreteau, Guillaume; Pons-Tostivint, Elvire.

Afiliação

Denis MG; Nantes Université, CHU Nantes, Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, Nantes, France.
Herbreteau G; Nantes Université, CHU Nantes, Department of Biochemistry, INSERM, CNRS, Immunology and New Concepts in Immunotherapy, Nantes, France.
Pons-Tostivint E; Nantes Université, CHU Nantes, Department of Medical Oncology, Nantes, France.

Transl Lung Cancer Res ; 12(2): 200-203, 2023 Feb 28.

Article em En | MEDLINE | ID: mdl-36895928